Chiara Riganti

Chiara Riganti is a Professor in the Department of Oncology at the University of Turin. Her research focuses on molecular mechanisms of drug resistance in cancer, particularly the interplay between tumor microenvironment, nitric oxide signaling, and chemotherapy/immunotherapy resistance. She leads initiatives in translational oncology and molecular medicine, contributing to drug development strategies targeting resistant tumor phenotypes.

• Education: Advanced degrees in Biochemistry and Molecular Biology (details not specified in text)
• Academic Roles:
  • Member of Department Council and Research Commission at Department of Oncology
  • Coordinator of PhD programs in Molecular Medicine and Translational Oncology

Her research integrates cancer cell biology with metabolic and immune mechanisms. Key areas include:

• Cross-talk between chemo- and immuno-resistance
• Nitric oxide regulation in tumor proliferation/apoptosis
• Targeting lipid metabolism to overcome therapy resistance

Recent work highlights tumor microenvironment roles in mesothelioma prognosis and novel combination therapies for triple-negative breast cancer. She collaborates internationally on immunogenic cell death mechanisms and lipid-based chemosensitizers.

Academic Service: Serves on institutional committees for research, third mission activities, and graduate education.